Search PubMed⌕ Search

Biomedical subjects

D Donadio

Publications and source records attributed to D Donadio.

50 records · Page 3Linked to original sources
PubMed1983

[Bullous pemphigoid treated by plasma exchange. Open study in 10 patients].

Ten patients with bullous pemphigoid underwent low volume plasma exchange (1/3 to 1/2 of the plasmatic mass) 3 times a week for 2 to 6 weeks followed, in some of them, by maintenance corticosteroid therapy. Eight patients benefited from this treatment. Complete control of the disease was obtained with PE alone in 3: low-dose corticosteroids were sufficient to procure remission in 2, and dosage could be reduced in 3 patients who previously required high doses of corticosteroids. No serious side-effects were recorded. The best results were observed in patients who had been ill for less than 3 months. Thus, low volume plasma exchanges make it possible to obtain clinical improvement while avoiding the rebound phenomena sometimes observed after high volume plasma exchanges. Circulating immune complexes and pemphigoid antibodies usually decreased under treatment, but there was no close correlation between these changes and therapeutic effectiveness.

Adrenal Cortex Hormones↗
PubMed1981

[Our experince with antiglobulin consumption (Dixon test) in the study of antibodies bound to platelets].

We measured the quantity of IgG bound to platelets (IgGP) by the antiglobulin consumption test (Dixon technic). In controls, the IgG level did not exceed 10 X 10(-15) g for one platelet. The amount of IgGP was often incraeased (more than 10 X 10(-l5) g) in some autoimmune diseases as lupus erythematosus, chronic lymphocytic leukemia and chronic active hepatitis. Among 26 patients presenting an idiopathic thrombocytopenic purpura (ITP) with a low number of platelets, 21 (77%) had a high titer of IgGP. In 6 ITP in remission, the IgGP titer was normal. After a review of the different technics detecting the IgG bound to platelets, we explain why we choose the antiglobulin consumption. This test is excellent for the research of anti-platelets auto-antibodies in ITP. Yet, the reaction remains negative in a minority of ITP. Several explanations are possible: low quantity of IgGP, presence of other anto-antibodies as IgM or IgA, cellular auto-immunity anti-platelets without antibodies, non immunologic ITP.

Antibodies↗
PubMed1981

[Serum beta-2-microglobulin in multiple myeloma. Practical value].

The concentration of serum, beta-2-microglobulin (S beta 2m) and the ratio measured S 2m/theoretical S beta 2m M/TH were evaluated in 69 patients with multiple myeloma (MM) and compared with healthy subjects and with patients with a benign monoclonal gammapathy. The concentration of S beta 2m and the ratio S beta 2m M/TH are higher in multiple myeloma than in controls and are strongly correlated with the plasma cell mass On the other hand, no difference was noted concerning the S beta 2m and the ration S beta 2m M/TH between benign monoclonal gammopathy and multiple myeloma at stage I of Durie and Salmon. Under chemotherapy, the variations in concentrations of S beta 2m and of the ratio S beta 2m M/TH are strongly correlated with those of the tumour mass. Beta 2m is not very useful for the differential diagnosis between benign monoclonal gammapathy and multiple myeloma. Beta 2m is very useful in the prognosis of MM, permitting one to assess accurately the tumour mass and the response to treatment, particularly in cases of deficiency of the usual markers.

Beta-Globulins↗
PubMed1981

[Therapeutic failures in early stages of Hodgkin's disease : causes and prevention (author's transl)].

A retrospective study of 65 patients with Hodgkin's disease (clinical stage I: 11 cases; stage II: 54 cases) included an analysis of the causes of therapy failure. Twenty-five of the 65 patients had been treated by regional irradiation (thoracic mantle or inverted Y field) restricted to only one side of the diaphragm; 27 patients had received the same irradiation followed by chemotherapy (MOPP). The subjects were irradiated on both sides of the diaphragm; 3 of these had received the same radiotherapy followed by chemotherapy (MOPP). Relapses in the irradiated fields were rare. Relapses in the areas bordering the irradiated fields were definitely the result of faulty delivery. Better evaluation of the precise extent of the disease, particularly by laparotomy, would lead to improved initial treatment (radio- or chemotherapy). The availability of improved irradiation techniques and a better choice of indications, particularly concerning the timing for chemotherapy, should result in maximal reduction of therapeutic failures in the early stages of Hodgkin's disease.

Antineoplastic Agents↗
PubMed1979

[Multiple myeloma of bones. Retrospective study of prognostic factors based on a series of 243 patients].

The authors have made a retrospective study of 243 cases of multiple myelomas, most of them treated with alkylating agents. The average age at the time of diagnosis was 65 years (+ 10). The ratio of the sexes was 1 : 1. Seventy two per cent of the patients had a bone rating of 2 or 3 according to the criteria of Durie and Salmon. Fifty-eight per cent of the patients were anemic (Hg 12 g per cent), with less than 15 per cent being leucopenic or thrombopenic. Hypercalcemia (105 mg 0/00) was noted in 27 per cent of cases. The distribution of immunochemical types is as follows : IgG, 51.5 per cent; IgA, 28 per cent; pure Bence Jones, 20.5 per cent. The respective percentages of kappa and lambda light chains were 64.2 per cent and 35.8 per cent. In this series, nearly 80 per cent of the patients were at phase III according to the classification of Durie and Salmon, and 30.8 per cent at phase B. The median survival, including all phases, increased from 8 months without alkylating agent, to 20 months with melphalan and/or cyclophosphamide. The factors influencing the survival of the patients treated were age, the hemoglobin level, calcemia, renal deficiencies, the immunochemical type, the stage of the disease, and the response to alkylating treatment. The value of these different prognostic factors is discussed.

Adult↗
PubMed1979

[Eosinophilic gastroenteritis in 2 child].

A boy aged 12 years is described who had eosinophilic gastroenteritis, a rare condition in childhood and one that is difficult to diagnose. Eosinophilia in the peripheral blood is a useful diagnostic clue. Although the histological appearances suggest an allergic process, the aetiology is unknown.

Child↗
PubMed1978

[Recurrent familial thromboembolic disease due to congenital deficiency in anti-thrombin III. Preliminary study of 3 cases (author's transl)].

The three cases reported, two mesenteric venous infarctions and one asymptomatic carrier, prove the responsibility of the anti-thrombin III deficiency in the development of apparently primary entero-mesenteric venous infarctions. Thus such a deficiency should be sought routibs. Furthermore, these 3 cases confirm the usual characteristics of the 10 familial cases collected since the princeps description of Egeberg: recurrent thromboembolic disease in the young subject involving essentially the lower limbs, relative resistance to heparin, family history of thromboembolic disease confirming the hereditary nature of the disease with dominant transmission, laboratory confirmation of the quantitative deficiency in antithrombin III, the levels and activity of which are reduced by half, and decrease in laboratory sensitivity to heparin contrasting with normal clotting studies. The family history reveals associated conditions within the syndrome: asthma and Biermer's anemia as well as similarities in leucocyte HLA groups.

Antithrombin III Deficiency↗
PubMedDate not supplied

Long-term and preventive effects of sublingual allergen-specific immunotherapy: a retrospective, multicentric study.

There is now an increasing body of evidence to support the practice of allergen-specific sublingual-swallow immunotherapy (SLIT) in the treatment of IgE-mediated respiratory allergies. Recent studies on traditional injection therapy have pointed out that this form of treatment is not only capable to decrease actual allergic symptoms, but may also have long-term clinical and preventive effects and may influence atopy natural history. In the year 2000, our group published a retrospective, multicenter study showing the efficacy and safety of SLIT in a survey of 302 patients. We now carried out a second study on the same patients, with the aim of investigating long-term and preventive effects of SLIT. Beside the well-known safety and efficacy of this treatment (80.8% of patients reported clinical benefits), SLIT proved also to elicit long term clinical effects: over a mean follow-up of 11.6 months after the end of treatment, 80.8% of patients still maintained the previously achieved benefits. During the follow-up period, only 1% of non-asthma patients reported an onset of respiratory symptoms, and only 9.6% of patients undergoing new skin tests showed new sensitizations. All the clinical benefits were strongly linked to the length of treatment: patients with long-lasting benefits were treated for a mean length of 29.1 months, while patients showing a return to pre-SLIT condition were treated for a mean 13.3 months. SLIT can obtain long-term and preventive effects so far attributed to injection immunotherapy.

Administration, Sublingual↗
PubMedDate not supplied

Safety and efficacy evaluation of sublingual allergen-specific immunotherapy a retrospective, multicenter study.

In recent years, several controlled studies have proved the efficacy and safety of sublingual specific immunotherapy, as a possible alternative to the classic subcutaneous route of administration. This alternative option has been officially confirmed by the recent WHO position paper "Allergen Immunotherapy: Therapeutic Vaccines for Allergic Diseases'". Since sublingual immunotherapy has now been widely used for years, we carried out an open, multicentric, retrospective study to investigate the efficacy and safety of this form of treatment in a large number of patients. To this end, we studied 302 subjects undergoing sublingual immunotherapy for at least three months with different allergen compositions. Notwithstanding the obvious limitations due to the study design, this survey has confirmed the high efficacy and safety of this form of treatment, as already reported in previous controlled studies. Sublingual immunotherapy appears to be a simple, well-tolerated and effective method of treatment of allergen-specific diseases.

Journal Article↗